{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:39Z","timestamp":1793103339079,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It has been documented that Crohn\u2019s disease\u00a0(CD) patients were prone to develop non-alcoholic liver fatty liver disease (NAFLD) with less metabolic factors. Our purpose is to investigate the prevalence, clinical characteristics and possible indicators for NAFLD in a cohort of Chinese patients with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Established CD patients who underwent magnetic resonance enterography (MRE) at the gastroenterology unit of our hospital were consecutively enrolled between June 2018 and May 2020. The diagnosis of NAFLD was made by magnetic resonance proton density fat fraction (MR-PDFF) maps. Medical records during hospitalization were collected and examined by univariate and multivariate analyses. Then a predictive model was constructed based on logistic regression analysis to evaluate the risk of developing NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 340 CD subjects were enrolled in this study, 83 (24.4%) suffered from NAFLD. Compared with those without NAFLD, patients with NAFLD showed longer disease duration, higher body mass index (BMI), more frequent use of corticosteroid and pronouncedly elevated liver function tests. The comparison showed no difference in terms of prolonged anti tumor necrosis factor-\u03b1 (TNF-\u03b1) use (&gt;\u200954w). Multivariate analysis demonstrated that BMI, serum transaminase, pre-albumin and disease duration could independently predict hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NAFLD is frequent in chronic CD patients, while long term use of anti TNF-\u03b1 seems to have no impact on the development of NAFLD in this population. The model incorporating duration, serum transaminase and body mass index presented as a clinical nomogram could well predict the risk of NAFLD in patient with CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02238-5","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T02:03:42Z","timestamp":1649729022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Qijin","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"2238_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.autrev.2014.01.029","volume":"13","author":"MW Laass","year":"2014","unstructured":"Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn\u2019s disease. Autoimmun Rev. 2014;13:467\u201371.","journal-title":"Autoimmun Rev"},{"key":"2238_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2238_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"2238_CR4","doi-asserted-by":"publisher","first-page":"E372","DOI":"10.3390\/nu12020372","volume":"12","author":"P Balestrieri","year":"2020","unstructured":"Balestrieri P, Ribolsi M, Guarino MPL, Emerenziani S, Altomare A, Cicala M. Nutritional aspects in inflammatory bowel diseases. Nutrients. 2020;12:E372.","journal-title":"Nutrients"},{"key":"2238_CR5","first-page":"2816","volume":"17","author":"S McHenry","year":"2019","unstructured":"McHenry S, Sharma Y, Tirath A, Tsai R, Mintz A, Fraum TJ, et al. Crohn\u2019s disease is associated with an increased prevalence of nonalcoholic fatty liver disease: a cross-sectional study using magnetic resonance proton density fat fraction mapping. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17:2816\u20138.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2238_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/MIB.0000000000001085","volume":"23","author":"K Glassner","year":"2017","unstructured":"Glassner K, Malaty HM, Abraham BP. Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:998\u20131003.","journal-title":"Inflamm Bowel Dis"},{"key":"2238_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2238_CR8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-64.","journal-title":"J Hepatol"},{"key":"2238_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ibd\/izy200","volume":"25","author":"C Saroli Palumbo","year":"2019","unstructured":"Saroli Palumbo C, Restellini S, Chao C-Y, Aruljothy A, Lemieux C, Wild G, et al. Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography. Inflamm Bowel Dis. 2019;25:124\u201333.","journal-title":"Inflamm Bowel Dis"},{"key":"2238_CR10","first-page":"10633","volume":"10","author":"D Li","year":"2017","unstructured":"Li D, Lu C, Yu C. High incidence of non-alcoholic fatty liver disease in patients with Crohn\u2019s disease but not ulcerative colitis. Int J Clin Exp Pathol. 2017;10:10633\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"2238_CR11","first-page":"463","volume":"32","author":"A Likhitsup","year":"2019","unstructured":"Likhitsup A, Dundulis J, Ansari S, Patibandla S, Hutton C, Kennedy K, et al. High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy. Ann Gastroenterol. 2019;32:463\u20138.","journal-title":"Ann Gastroenterol"},{"key":"2238_CR12","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","volume":"26","author":"P Hoffmann","year":"2020","unstructured":"Hoffmann P, Jung V, Behnisch R, Gauss A. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a cross-sectional and longitudinal analysis. World J Gastroenterol. 2020;26:7367\u201381.","journal-title":"World J Gastroenterol"},{"key":"2238_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ibd.21336","volume":"17","author":"CS Coffin","year":"2011","unstructured":"Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-\u03b1) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:479\u201384.","journal-title":"Inflamm Bowel Dis"},{"key":"2238_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/ibd\/izy128","volume":"24","author":"TG Simon","year":"2018","unstructured":"Simon TG, Van Der Sloot KWJ, Chin SB, Joshi AD, Lochhead P, Ananthakrishnan AN, et al. IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2018;24:2247\u201357.","journal-title":"Inflamm Bowel Dis"},{"key":"2238_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz324","author":"S McHenry","year":"2020","unstructured":"McHenry S, Tirath A, Tsai R, Sharma Y, Flores AG, Davidson NO, et al. Derivation and internal validation of a clinical prediction tool to predict nonalcoholic fatty liver disease in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2020. https:\/\/doi.org\/10.1093\/ibd\/izz324.","journal-title":"Inflamm Bowel Dis"},{"key":"2238_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jgh.15185","volume":"36","author":"Z Ran","year":"2021","unstructured":"Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, et al. Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021;36:637\u201345.","journal-title":"J Gastroenterol Hepatol"},{"key":"2238_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00004836-200305000-00012","volume":"36","author":"S Bargiggia","year":"2003","unstructured":"Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417\u201320.","journal-title":"J Clin Gastroenterol"},{"key":"2238_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144\u201364.","journal-title":"J Crohns Colitis"},{"key":"2238_CR19","doi-asserted-by":"publisher","first-page":"E1005","DOI":"10.3390\/cells9041005","volume":"9","author":"VA Piazzolla","year":"2020","unstructured":"Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020;9:E1005.","journal-title":"Cells"},{"key":"2238_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1148\/radiol.12120896","volume":"267","author":"A Tang","year":"2013","unstructured":"Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267:422\u201331.","journal-title":"Radiology"},{"key":"2238_CR21","unstructured":"Assessing the calibration of mortality benchmarks in critica...\u202f: Critical Care Medicine. https:\/\/journals.lww.com\/ccmjournal\/Abstract\/2007\/09000\/Assessing_the_calibration_of_mortality_benchmarks.7.aspx. Accessed 2 Sep 2021."},{"key":"2238_CR22","doi-asserted-by":"publisher","unstructured":"A simple, step-by-step guide to interpreting decision curve analysis|Diagnostic and Prognostic Research|Full Text. https:\/\/diagnprognres.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s41512-019-0064-7. Accessed 2 Sep 2021.","DOI":"10.1186\/s41512-019-0064-7"},{"key":"2238_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet Lond Engl. 2017;389:1741\u201355.","journal-title":"Lancet Lond Engl"},{"key":"2238_CR24","first-page":"1268","volume":"18","author":"NH Nguyen","year":"2020","unstructured":"Nguyen NH, Singh S, Sandborn WJ. Positioning therapies in the management of Crohn\u2019s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;18:1268\u201379.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2238_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/hepr.12828","volume":"47","author":"S Sagami","year":"2017","unstructured":"Sagami S, Ueno Y, Tanaka S, Fujita A, Hayashi R, Oka S, et al. Significance of non-alcoholic fatty liver disease in Crohn\u2019s disease: a retrospective cohort study. Hepatol Res Off J Jpn Soc Hepatol. 2017;47:872\u201381.","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"2238_CR26","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/j.crohns.2012.10.015","volume":"7","author":"A Sourianarayanane","year":"2013","unstructured":"Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e279-285.","journal-title":"J Crohns Colitis"},{"key":"2238_CR27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69:896\u2013904.","journal-title":"J Hepatol"},{"key":"2238_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1\u201310.","journal-title":"Clin J Gastroenterol"},{"key":"2238_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","volume":"17","author":"A Lavelle","year":"2020","unstructured":"Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:223\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2238_CR30","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1186\/s12876-022-02297-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000}}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02238-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:14:20Z","timestamp":1652426060000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02238-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02238-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1223753\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12876-022-02297-8","URL":"https:\/\/doi.org\/10.1186\/s12876-022-02297-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the Declaration of Helsinki and approved by Shanghai Jiaotong University, School of Medicine, Renji Hospital Ethics Committee. As it is a retrospective cohort study, informed consent is waived, which is granted by the Shanghai Jiaotong University, School of Medicine, Renji Hospital Ethics Committee. (KY-2021-122-B).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}